INT194504

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 2006
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 27
Total Number 32
Disease Relevance 7.45
Pain Relevance 2.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Smad2) intracellular (Smad2) protein complex (Smad2)
transcription factor binding (Smad2) cytoplasm (Smad2)
Anatomy Link Frequency
articular 2
chondrocytes 2
retinas 2
MC3T3-E1 1
F4/80 1
Smad2 (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 97 98.80 Very High Very High Very High
fibrosis 242 98.08 Very High Very High Very High
agonist 150 97.36 Very High Very High Very High
Osteoarthritis 646 94.48 High High
Spinal cord 96 91.12 High High
Inflammation 216 89.92 High High
antagonist 24 86.52 High High
imagery 7 75.84 Quite High
intrathecal 24 72.32 Quite High
Arthritis 8 70.44 Quite High
Disease Link Frequency Relevance Heat
Aging 96 99.04 Very High Very High Very High
Fibrosis 271 98.08 Very High Very High Very High
Hypertrophy 35 97.32 Very High Very High Very High
Ganglion Cysts 39 97.16 Very High Very High Very High
Sclerosis 19 96.28 Very High Very High Very High
Targeted Disruption 21 95.00 High High
Osteoarthritis 681 94.48 High High
Neuropathic Pain 76 93.32 High High
Apoptosis 104 91.04 High High
INFLAMMATION 239 89.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RI/II and the phosphorylation states of receptor-regulated Smad2/3, as well as the expression of the common mediator Smad 4.
Gene_expression (expression) of Smad2
1) Confidence 0.65 Published 2009 Journal Mol Pain Section Body Doc Link PMC2669449 Disease Relevance 0.82 Pain Relevance 0.53
After the transfer, blots were incubated overnight at 4°C with the following antibodies as per manufacturer's instructions: goat anti-p-Smad2/3 (1:500, Santa Cruz); goat anti-Smad4 (1:250, Santa Cruz); rabbit anti-Iba-1 (1:500, Wako); and goat anti-TGF-?
Gene_expression (/) of Smad2
2) Confidence 0.65 Published 2009 Journal Mol Pain Section Body Doc Link PMC2669449 Disease Relevance 0.13 Pain Relevance 0.06
In the absence of TSA, pSmad2 was detected in cell nuclei at 0.5 and 1.0 h post-TGF?
Gene_expression (detected) of pSmad2
3) Confidence 0.44 Published 2010 Journal Molecular Vision Section Body Doc Link PMC3013068 Disease Relevance 0 Pain Relevance 0.04
Immunocytochemistry showed that even a low TSA dose (10 nM) suppressed translocation of pSmad2 to the nuclei whereas high doses of TSA (200 and 500 nM) eliminated the pSmad2 signal from the cell nuclei as no pSmad2 expression was detected in the cell nuclei at these 2 TSA doses.
Neg (no) Gene_expression (expression) of pSmad2
4) Confidence 0.44 Published 2010 Journal Molecular Vision Section Body Doc Link PMC3013068 Disease Relevance 0 Pain Relevance 0
1 addition (Figure 2B); whereas in the presence of TSA (10 nM), phospho-Smad2 was detected in the nuclei after 0.5 h.
Gene_expression (detected) of Smad2
5) Confidence 0.44 Published 2010 Journal Molecular Vision Section Body Doc Link PMC3013068 Disease Relevance 0.06 Pain Relevance 0.05
Genes monitored were smad2, smad3, TGF-?
Gene_expression (Genes) of smad2
6) Confidence 0.42 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2659748 Disease Relevance 0.27 Pain Relevance 0
In articular chondrocytes treated with azacytidine, reduced Smad2 and Smad3 expression and signaling and increased Smad1/5 expression correlated with elevated synthesis of type X collagen and alkaline phosphatase.
Gene_expression (expression) of Smad2 in articular
7) Confidence 0.40 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875624 Disease Relevance 0.44 Pain Relevance 0.03
on chondrocyte maturation is mediated by the Smad2/3 pathway, as has been shown by overexpression of dominant negative Smad2 and Smad3 in chondrocytes.
Gene_expression (overexpression) of Smad2 in chondrocyte
8) Confidence 0.40 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875624 Disease Relevance 0.20 Pain Relevance 0
Expression of non phosphorylated Smad2 was not altered during ageing.
Gene_expression (Expression) of Smad2 associated with aging
9) Confidence 0.40 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875624 Disease Relevance 0.75 Pain Relevance 0.20
Overexpression of both Smad2 and Smad3 blocked spontaneous maturation in Smad3-deficient chondrocytes [70,71].
Gene_expression (Overexpression) of Smad2 in chondrocytes
10) Confidence 0.40 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875624 Disease Relevance 0.18 Pain Relevance 0.03
Western blot analysis of samples treated with 200 nM TSA did not completely block phosphorylation of Smad2; instead, it faintly reduced the pSmad2 levels at 2 h post-TGF?
Gene_expression (levels) of pSmad2
11) Confidence 0.38 Published 2010 Journal Molecular Vision Section Body Doc Link PMC3013068 Disease Relevance 0.05 Pain Relevance 0
TSA at the concentrations of 200 and 500 nM abolished pSmad2 nuclear expression (Figure 2B).


Gene_expression (expression) of pSmad2
12) Confidence 0.38 Published 2010 Journal Molecular Vision Section Body Doc Link PMC3013068 Disease Relevance 0.07 Pain Relevance 0.05
RT-PCR of cDNA collected from adult mouse retinas revealed the expression of smad2, smad3, TGF-?
Gene_expression (expression) of smad2 in retinas
13) Confidence 0.37 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2659748 Disease Relevance 0.17 Pain Relevance 0
The expression of TGF-receptors and pp-smad2 in normal retinas suggests that TGF-?
Gene_expression (expression) of smad2 in retinas
14) Confidence 0.37 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2659748 Disease Relevance 0.66 Pain Relevance 0.03
BMP-2 increased pSMAD1 levels, and also reduced pSMAD2 levels.
Gene_expression (levels) of pSMAD2
15) Confidence 0.37 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2896919 Disease Relevance 0.11 Pain Relevance 0.03
1 signaling indicates that it acts primarily via pSMAD2, we observed in the MC3T3-E1 system that exogenous TGF-?
Gene_expression (acts) of pSMAD2 in MC3T3-E1
16) Confidence 0.37 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2896919 Disease Relevance 0.12 Pain Relevance 0.03
The phosphorylated (pSMAD1, pSMAD2) forms of the protein were examined by western blotting, with total SMAD1 and ?
Gene_expression (forms) of pSMAD2
17) Confidence 0.37 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2896919 Disease Relevance 0.17 Pain Relevance 0
SB431542 both reduced pSMAD2 and increased pSMAD1, suggesting a sophisticated signaling mechanism for this compound.


Gene_expression (reduced) of pSMAD2
18) Confidence 0.37 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2896919 Disease Relevance 0.14 Pain Relevance 0.04
The phosphorylated (pSMAD1, pSMAD2) forms of the protein were examined by western blotting, with total SMAD1 and ?
Spec (examined) Gene_expression (examined) of pSMAD2
19) Confidence 0.37 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2896919 Disease Relevance 0.17 Pain Relevance 0
1 treatment suppressed pSMAD1 and that pSMAD2 levels were unchanged.
Gene_expression (levels) of pSMAD2
20) Confidence 0.37 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2896919 Disease Relevance 0.13 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox